trending Market Intelligence /marketintelligence/en/news-insights/trending/yebm4ho7utqizc_k5tmxjw2 content esgSubNav
In This List

Eleven Biotherapeutics regains compliance with Nasdaq listing requirements

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Eleven Biotherapeutics regains compliance with Nasdaq listing requirements

Eleven Biotherapeutics Inc. said it regained compliance with Nasdaq Stock Market LLC's $1 minimum bid price listing requirement.

The Cambridge, Mass.-based company received a noncompliance notice from the Nasdaq in December 2017 as the closing bid price of the company's common stock was below $1 per share for 30 consecutive business days.

Nasdaq confirmed that the company regained compliance after the closing bid price for its common stock had been at $1 per share or greater for a minimum of 10 consecutive business days.